Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

STOK

Stoke Therapeutics (STOK)

Stoke Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:STOK
DateTimeSourceHeadlineSymbolCompany
27/02/202508:30Business WireStoke Therapeutics to Present at Upcoming Investor Conferences in MarchNASDAQ:STOKStoke Therapeutics Inc
19/02/202508:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STOKStoke Therapeutics Inc
19/02/202500:00Business WireBiogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental ImpairmentsNASDAQ:STOKStoke Therapeutics Inc
19/02/202500:00GlobeNewswire Inc.Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental ImpairmentsNASDAQ:STOKStoke Therapeutics Inc
09/01/202508:30Business WireStoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:STOKStoke Therapeutics Inc
07/01/202523:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STOKStoke Therapeutics Inc
07/01/202523:00Business WireStoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
07/01/202508:30Business WireStoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
28/12/202409:23Edgar (US Regulatory)Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:STOKStoke Therapeutics Inc
28/12/202409:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
24/12/202410:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:STOKStoke Therapeutics Inc
12/12/202408:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
12/12/202408:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
11/12/202411:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
11/12/202411:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
10/12/202408:48Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:STOKStoke Therapeutics Inc
07/12/202409:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STOKStoke Therapeutics Inc
07/12/202404:00Business WireStoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
06/12/202408:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
06/12/202408:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
04/12/202423:00Business WireStoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet SyndromeNASDAQ:STOKStoke Therapeutics Inc
04/12/202408:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
04/12/202408:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
03/12/202400:00Business WireStoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual MeetingNASDAQ:STOKStoke Therapeutics Inc
15/11/202401:00Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:STOKStoke Therapeutics Inc
06/11/202408:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:STOKStoke Therapeutics Inc
06/11/202408:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:STOKStoke Therapeutics Inc
05/11/202423:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:STOKStoke Therapeutics Inc
05/11/202423:00Business WireStoke Therapeutics Reports Third Quarter Financial Results and Provides Business UpdatesNASDAQ:STOKStoke Therapeutics Inc
02/11/202407:50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:STOKStoke Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:STOK